Servier and CTI BioPharma Corp. will expand their agreement regarding Pixuvri, which will give Servier rights to sell it anywhere but the USA.
For that, Servier will pay $12 million to CTI BioPharma, and possibly another €76 million from sales and regulatory milestone payments as well as royalties on net product sales.
Pixuvri has been granted conditional marketing authorization from the European Commission for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma (NHL).
As a specific post-authorization requirement, Pixuvri is currently being investigated in a Phase III clinical trial, PIX306. If positive, the results from this trial will confirm the treatment’s current indication and could support broader indications.
“Over the past three years, we have worked hand in hand with our partner, CTI BioPharma, to bring new treatment options to patients in Europe,” said U. Marion Schrenk, MD, Head of Therapeutic Area Oncology of Servier, noting the importance of leveraging the company’s expertise in these additional markets to ensure more eligible patients have access to Pixuvri.
“Oncology is an important focus for us, and we are fully committed to working with our partners, researchers and scientists to provide patients with novel therapeutic options in areas with high unmet needs,” said Shrenk.
Adam R. Craig, President and CEO of CTI BioPharma also added that he looks forward to the companies expanded partnership to complete the PIX306 trial in the near-term.